Home
Contact Careers rss
 

AVAC Calls for Speedy Funding of Critical Microbicide Follow-Up Studies

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.  See below for full announcement.

AttachmentSize
AVAC Calls for Speedy Funding of Critical Microbicide Follow-Up Studies PRESS RELEASE.pdf35.24 KB


Global HIV Vaccine Enterprise, 200 Park Ave. S. Suite 1501, New York, NY 10003 | +1 212-461-3692 or toll free at +1-866-966-4483

All Content ©2005 - 2010 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account